Overweight and obese adults who received weekly semaglutide injections and lifestyle advice for 12 weeks lost visceral fat by 21.3% and subcutaneous fat by 16.1%. The proportional reduction in visceral fat was significantly greater than in subcutaneous fat.
See the scientific wording
In overweight/obese adults, a 12-week intervention with once-weekly semaglutide and lifestyle advice resulted in a decrease in visceral fat mass by 0.36 kg (21.3% relative reduction), which was proportionally greater than the 0.37 kg (16.1%) reduction in subcutaneous fat (difference of 5.16 percentage points, P=0.009).
Correlational — new studies may shift this
ObservationalOne good-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Effects of once-weekly semaglutide on regional body composition in overweight or obese adults
Cohort StudyHuman
The study found that semaglutide plus lifestyle changes reduced deep belly fat by about 21% and fat under the skin by about 16%, matching the claim that belly fat decreased at a faster rate.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Semaglutide attaches to GLP-1 receptors on fat cells, which tells the body to break down fat for energy. This happens more in the deep belly fat because that fat is more active and has more receptors, so it shrinks faster than the fat under the skin.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Overweight and obese adults who received weekly semaglutide injections and lifestyle advice for 12 weeks lost visceral fat by 21.3% and subcutaneous fat by 16.1%. The proportional reduction in visceral fat was significantly greater than in subcutaneous fat.
Mechanism
1 studyThe drug semaglutide works by attaching to receptors on fat cells, telling the body to break down fat. Deep belly fat breaks down faster than fat under the skin because it is more active and has more of these receptors.
Semaglutide attaches to GLP-1 receptors on fat cells, which tells the body to break down fat for energy. This happens more in the deep belly fat because that fat is more active and has more receptors, so it shrinks faster than the fat under the skin.
Semaglutide, a GLP-1 receptor agonist, binds to and activates GLP-1 receptors on adipocytes and in the central nervous system, reducing appetite and caloric intake.
GLP-1 receptor activation enhances lipolysis and reduces lipid accumulation more in visceral adipose tissue due to its higher metabolic activity, richer blood supply, and greater receptor density.
Differential regional fat loss occurs, with visceral fat decreasing proportionally more than subcutaneous fat, as directly measured by DEXA.
Evidence from Studies
Supporting (1)
Community contributions welcome
The study found that semaglutide plus lifestyle changes reduced deep belly fat by about 21% and fat under the skin by about 16%, matching the claim that belly fat decreased at a faster rate.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of GLP-1 Agonists on Visceral Adipose Tissue Reduction
Meta-analysis of RCTs of semaglutide (any dose) in overweight/obese adults with measurements of visceral and subcutaneous fat via imaging (CT/MRI) before and after treatment, with subgroup analyses by dose, duration, and baseline characteristics.
Double-Blind Randomized Trial of Semaglutide 2.4 mg vs Placebo for Visceral Fat Loss Over 12 Weeks
Double-blind, placebo-controlled RCT with 12-week intervention of once-weekly semaglutide (2.4 mg) + lifestyle advice vs placebo + lifestyle advice in overweight/obese adults (BMI ≥27). Primary outcome: change in visceral fat area (cm²) by CT. Secondary outcomes: subcutaneous fat, total fat, weight, HbA1c. Duration: 12 weeks treatment, 6 months follow-up.
Prospective Cohort Study of Semaglutide and Changes in Regional Fat Depots Over 1 Year
Prospective cohort of overweight/obese adults initiating semaglutide (any dose) as part of routine care, with baseline and follow-up imaging (CT/MRI) at 6 and 12 months. Compare changes in visceral and subcutaneous fat, adjusting for confounders (diet, exercise, comorbidities).
Animal Model Study: Effect of Semaglutide on Visceral vs Subcutaneous Adipose Tissue in Diet-Induced Obese Mice
Diet-induced obese mice treated with semaglutide (equivalent human dose) vs vehicle for 12 weeks. Measure visceral (epididymal) and subcutaneous fat pad weights, adipocyte size, gene expression of lipolytic and inflammatory markers, and GLP-1 receptor expression.